In C57BL/6 mice, DMP 777 treatment significantly increased gastric FOXL1+/PDGFRα+/DAPI+ telocyte counts compared with untreated stomachs. Extended treatment reduced telocyte distribution at the top of the gland and increased their presence in the middle and basal regions. After 3 days of DMP 777 treatment, miR-148a was down-regulated in chief cells without GSII expression. After 10 days of treatment, miR-148a expression was significantly decreased. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Gastric Telocyte Counts Following Treatment
Animal study · Approximately 8 weeks C57BL/6 mice; n = 5 for Untreated and n = 4 for DMP-777 and L635 [1]
C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily for up to 10 consecutive days. Treated stomachs showed a significant increase in FOXL1+/PDGFRα+/DAPI+ telocyte counts compared with untreated stomachs.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- once a day for up to 10 consecutive days
- Vehicle
- 1% methylcellulose
- DMP 777 350 mg/kg
- Model: Approximately 8 weeks C57BL/6 mice; n = 5 for Untreated and n = 4 for DMP-777 and L635
Methods and source locations
Compound reported in the paper: DMP 777
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > FOXL1+/PDGFRα+ Double-Positive Telocytes Are Increased During Metaplasia Development in the Stomach (S23); Materials and Methods > Mice (S113, S114); Figure 2 legend (S172, S174)
Quantification of telocyte count: Quantification of telocyte count; comparator: untreated stomach — Results > FOXL1+/PDGFRα+ Double-Positive Telocytes Are Increased During Metaplasia Development in the Stomach (S23); Figure 2 legend (S172)
DMP 777 350 mg/kg · Results > FOXL1+/PDGFRα+ Double-Positive Telocytes Are Increased During Metaplasia Development in the Stomach (S23); Materials and Methods > Mice (S114)
Chief Cell miR-148a Following Treatment
Animal study · Eight-week-old C57BL/6 mice; 3 mice were used per group [2]
C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily for 3 days. Fluorescence in situ hybridization showed down-regulation of miR-148a in chief cells without GSII expression.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- once a day; 3 days
- Vehicle
- 1% methylcellulose
- DMP 777 350 mg/kg
- Model: Eight-week-old C57BL/6 mice; 3 mice were used per group
Methods and source locations
Compound reported in the paper: DMP 777
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S24); Materials and Methods > Mice (S60, S61, S62); Figure 3 legend (S157)
Fluorescence in situ hybridization for miR-148a: Fluorescence in situ hybridization for miR-148a; comparator: normal chief cells — Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S24); Figure 3 legend (S157)
DMP 777 350 mg/kg · Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S24); Materials and Methods > Mice (S62)
Telocyte Distribution Within Gastric Glands Following Treatment
Animal study · Approximately 8 weeks C57BL/6 mice; n = 4, except for DMP-777 3 Days, n = 3 [1]
C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily, with telocyte distribution assessed after 1, 3, and 10 days. Extended treatment reduced telocyte distribution at the top and increased their presence in the middle and basal regions of the gland.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- 1, 3, and 10 days; once a day
- Vehicle
- 1% methylcellulose
- DMP 777 350 mg/kg
- Model: Approximately 8 weeks C57BL/6 mice; n = 4, except for DMP-777 3 Days, n = 3
Methods and source locations
Compound reported in the paper: DMP 777
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Telocytes Show Altered Distribution Near the Expanding Proliferative Zone in DMP-777-Treated Mouse Stomach (S28, S29); Materials and Methods > Mice (S113, S114); Figure 3 legend (S184, S188, S189)
Quantification of telocyte distribution within the gland: Quantification of telocyte distribution within the gland; comparator: untreated stomach tissue — Figure 3 legend (S184, S188)
DMP 777 350 mg/kg · Results > Telocytes Show Altered Distribution Near the Expanding Proliferative Zone in DMP-777-Treated Mouse Stomach (S28); Materials and Methods > Mice (S114); Figure 3 legend (S188)
Chief Cell miR-148a Staining Following Extended Treatment
Animal study · Eight-week-old C57BL/6 mice; 3 mice were used per group [2]
C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily for 10 days. Quantification of relative staining intensity showed significantly decreased miR-148a expression.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- once a day; 10 days
- Vehicle
- 1% methylcellulose
- DMP 777 350 mg/kg
- Model: Eight-week-old C57BL/6 mice; 3 mice were used per group
Methods and source locations
Compound reported in the paper: DMP 777
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S23, S25); Materials and Methods > Mice (S60, S61, S62); Figure 3 legend (S158)
Quantitation of relative miR-148a staining intensity in chief cells and transdifferentiating chief cells at the base of the gland: Quantitation of relative miR-148a staining intensity in chief cells and transdifferentiating chief cells at the base of the gland; comparator: normal chief cells — Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S25); Figure 3 legend (S158)
DMP 777 350 mg/kg · Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S25); Materials and Methods > Mice (S62)